Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 19 articles: HTML format

Single Articles

May 2025
1. PAZ-ARES L, Borghaei H, Liu SV, Peters S, et al
   Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
   Lancet. 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011.
   PubMed     Abstract available
   
   
   March 2025
2. XIONG A, Wang L, Chen J, Wu L, et al
   Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
   Lancet. 2025;405:839-849.
   PubMed     Abstract available
   
   
   September 2024
3. SPICER JD, Garassino MC, Wakelee H, Liberman M, et al
   Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3
   Lancet. 2024 Sep 12:S0140-6736(24)01756-2. doi: 10.1016/S0140-6736(24)01756.
   PubMed     Abstract available
   
   
   
4. PRESLEY CJ, Owen DH
   Improved survival for patients with lung cancer treated with perioperative immunotherapy.
   Lancet. 2024 Sep 12:S0140-6736(24)01920-2. doi: 10.1016/S0140-6736(24)01920.
   PubMed    
   
   
   August 2024
5. MEYER ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, et al
   New promises and challenges in the treatment of advanced non-small-cell lung cancer.
   Lancet. 2024 Aug 6:S0140-6736(24)01029-8. doi: 10.1016/S0140-6736(24)01029.
   PubMed     Abstract available
   
   
   July 2024
6. CHANG JY, Verma V, Heymach JV
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer - Authors' reply.
   Lancet. 2024;404:241-242.
   PubMed    
   
   
   
7. HINDIE E
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
   Lancet. 2024;404:241.
   PubMed    
   
   
   
8. JIANG L, Yu J, Meng X
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
   Lancet. 2024;404:240-241.
   PubMed    
   
   
   June 2024
9. THE LANCET
   Lung cancer treatment: 20 years of progress.
   Lancet. 2024;403:2663.
   PubMed    
   
   
   May 2024
10. GIJTENBEEK RG, Noordhof AL, Asmara OD, Groen HJ, et al
    Immunotherapy in frail non-small-cell lung cancer patients.
    Lancet. 2024;403:1986.
    PubMed    
    
    
    March 2024
11. MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al
    Hidden metastatic lung tumour diagnosed by AI.
    Lancet. 2024;403:1290.
    PubMed    
    
    
    
12. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
    Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
    Lancet. 2024;403:860-861.
    PubMed    
    
    
    January 2024
13. PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al
    Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
    Lancet. 2024;403:145-146.
    PubMed    
    
    
    
14. OLIVIER T, Prasad V
    Sotorasib in KRAS(G12C) mutated lung cancer.
    Lancet. 2024;403:145.
    PubMed    
    
    
    
15. HANNA GG, McDonald F
    SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
    Lancet. 2024;403:122-124.
    PubMed    
    
    
    December 2023
16. CHU Q, Perrone F, Greillier L, Tu W, et al
    Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
    Lancet. 2023;402:2295-2306.
    PubMed     Abstract available
    
    
    
17. LEE YCG
    Pembrolizumab plus chemotherapy for pleural mesothelioma.
    Lancet. 2023;402:2266-2267.
    PubMed    
    
    
    
18. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available
    
    
    November 2023
19. SALMAN M, Fernandez Crespo R, Judah G
    Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.
    Lancet. 2023;402 Suppl 1:S82.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.